Willis Towers Watson Public Limited Company (WLTW) At $150.08 Forms Top; 1 Analysts Are Bullish Eleven Biotherapeutics, Inc. (EBIO) Last Week

April 15, 2018 - By Danny Collins

Willis Towers Watson Public Limited Company (NASDAQ:WLTW) Logo

Willis Towers Watson Public Limited Company (WLTW) formed multiple top with $156.08 target or 4.00% above today’s $150.08 share price. Willis Towers Watson Public Limited Company (WLTW) has $19.84B valuation. The stock increased 1.48% or $2.19 during the last trading session, reaching $150.08. About 563,560 shares traded or 0.77% up from the average. Willis Towers Watson Public Limited Company (NASDAQ:WLTW) has risen 16.43% since April 15, 2017 and is uptrending. It has outperformed by 4.88% the S&P500.

Among 3 analysts covering Eleven Biotherapeutics (NASDAQ:EBIO), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Eleven Biotherapeutics had 5 analyst reports since August 15, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Leerink Swann given on Saturday, August 15. The firm has “Market Perform” rating by Leerink Swann given on Tuesday, January 19. The company was downgraded on Tuesday, January 19 by Citigroup. The rating was maintained by Citigroup on Wednesday, March 16 with “Neutral”. See Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) latest ratings:

20/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $2 Initiates Coverage On

Analysts await Willis Towers Watson Public Limited Company (NASDAQ:WLTW) to report earnings on May, 3. They expect $4.00 EPS, up 7.82% or $0.29 from last year’s $3.71 per share. WLTW’s profit will be $528.86M for 9.38 P/E if the $4.00 EPS becomes a reality. After $2.21 actual EPS reported by Willis Towers Watson Public Limited Company for the previous quarter, Wall Street now forecasts 81.00% EPS growth.

Among 3 analysts covering Willis Towers Watson (NASDAQ:WLTW), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Willis Towers Watson has $146 highest and $115 lowest target. $130.50’s average target is -13.05% below currents $150.08 stock price. Willis Towers Watson had 4 analyst reports since January 7, 2016 according to SRatingsIntel. Bank of America downgraded Willis Towers Watson Public Limited Company (NASDAQ:WLTW) on Friday, January 27 to “Neutral” rating. JP Morgan initiated the stock with “Underweight” rating in Thursday, January 7 report. The firm earned “Outperform” rating on Friday, January 6 by Credit Suisse.

Investors sentiment increased to 2.25 in 2017 Q4. Its up 1.70, from 0.55 in 2017Q3. It is positive, as 2 investors sold Eleven Biotherapeutics, Inc. shares while 2 reduced holdings. 4 funds opened positions while 5 raised stakes. 1.80 million shares or 48.09% more from 1.21 million shares in 2017Q3 were reported. Fiduciary Tru Communications reported 0% of its portfolio in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Morgan Stanley owns 0% invested in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) for 12,062 shares. Blackrock holds 445,463 shares. 600 were accumulated by Citigroup. Panagora Asset Mgmt Inc has invested 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). California-based Parallax Volatility Advisers Lp has invested 0% in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Financial Bank Of Ny Mellon accumulated 44,849 shares. Geode Capital Mgmt Limited Liability Corporation stated it has 56,222 shares or 0% of all its holdings. 65,000 are owned by Bridgeway Mgmt Inc. Two Sigma Secs accumulated 65,152 shares or 0% of the stock. Citadel Advsr Ltd Limited Liability Company invested 0% of its portfolio in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO). Vanguard Gp owns 326,883 shares for 0% of their portfolio. 427,048 were accumulated by Virtu Ltd Com. Royal Fincl Bank Of Canada owns 0% invested in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) for 505 shares. Moreover, Northern Trust has 0% invested in Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) for 20,593 shares.

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) Institutional Positions Chart